Article
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Cancer chemotherapy and pharmacology - 1 May 2016
Kudo Kenichiro, Hotta Katsuyuki, Bessho Akihiro, Nogami Naoyuki, Kozuki Toshiyuki, Kuyama Shoichi, Inoue Koji, Harita Shingo, Okada Toshiaki, Gemba Kenichi, Fujii Masanori, Takigawa Nagio, Oda Naohiro, Tanimoto Mitsune, Kiura Katsuyuki
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy. METHODS: We retrospectively studied 49 consecutive patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.